- Home
- ABAT vs SAVA Comparison
ABAT vs SAVA Comparison
Compare ABAT & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABAT
- SAVA
- Stock Information
- Founded
- ABAT 2011
- SAVA 1998
- Country
- ABAT United States
- SAVA United States
- Employees
- ABAT N/A
- SAVA N/A
- Industry
- ABAT Metal Mining
- SAVA Biotechnology: Pharmaceutical Preparations
- Sector
- ABAT Basic Materials
- SAVA Health Care
- Exchange
- ABAT Nasdaq
- SAVA Nasdaq
- Market Cap
- ABAT 87.2M
- SAVA 70.5M
- IPO Year
- ABAT N/A
- SAVA N/A
- Fundamental
- Price
- ABAT $1.68
- SAVA $2.13
- Analyst Decision
- ABAT
- SAVA Buy
- Analyst Count
- ABAT 0
- SAVA 2
- Target Price
- ABAT N/A
- SAVA $54.50
- AVG Volume (30 Days)
- ABAT 2.7M
- SAVA 1.1M
- Earning Date
- ABAT 05-16-2025
- SAVA 08-07-2025
- Dividend Yield
- ABAT N/A
- SAVA N/A
- EPS Growth
- ABAT N/A
- SAVA N/A
- EPS
- ABAT N/A
- SAVA N/A
- Revenue
- ABAT $1,857,877.00
- SAVA N/A
- Revenue This Year
- ABAT $31,748.62
- SAVA N/A
- Revenue Next Year
- ABAT N/A
- SAVA N/A
- P/E Ratio
- ABAT N/A
- SAVA N/A
- Revenue Growth
- ABAT N/A
- SAVA N/A
- 52 Week Low
- ABAT $0.73
- SAVA $1.15
- 52 Week High
- ABAT $4.11
- SAVA $42.20
- Technical
- Relative Strength Index (RSI)
- ABAT 56.30
- SAVA 57.26
- Support Level
- ABAT $1.78
- SAVA $1.91
- Resistance Level
- ABAT $2.04
- SAVA $2.23
- Average True Range (ATR)
- ABAT 0.19
- SAVA 0.11
- MACD
- ABAT 0.03
- SAVA 0.03
- Stochastic Oscillator
- ABAT 56.47
- SAVA 78.12
About ABAT American Battery Technology Company
American Battery Technology Co is engaged in lithium-ion battery recycling, battery metals and material extraction, and resource production. It is a battery metals company producing low-cost battery metals with a commitment to closed-loop, clean energy technologies.
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.